Gyre Therapeutics, Inc. (GYRE)

NASDAQ: GYRE · Real-Time Price · USD

6.71

-0.16 (-2.33%)

Oct 13, 2026, 4:00 PM EDT - Market closed

Gyre Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-21.22	5.03	12.09	-92.93	2.3
Depreciation & Amortization	3.13	2.52	1.59	1.11	1.13
Loss (Gain) From Sale of Assets	0.02	0	0.07	3.34	0
Asset Writedown & Restructuring Costs	-	-	-	83.1	-
Loss (Gain) on Equity Investments	0.08	0.08	0.04	1.31	0.25
Stock-Based Compensation	9.87	7.16	0.83	7.28	13.37
Provision & Write-off of Bad Debts	0.07	-0.06	0.17	-0.06	0.02
Other Operating Activities	-6.85	4.55	4.44	6.02	1.4
Change in Accounts Receivable	-1.74	-10.81	-5.26	0.29	-7.92
Change in Inventory	-2.06	-3.63	-2.14	1.75	-0.88
Change in Accounts Payable	-0.55	0.01	-0.25	0.19	-0.11
Change in Income Taxes	0.92	0.04	-2.17	3	-1.34
Change in Other Net Operating Assets	5.19	-3.88	-13.05	11.49	2.46
Operating Cash Flow	-4.94	1.01	-3.64	25.89	10.68
Operating Cash Flow Growth	-	-	-	142.50%	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Capital Expenditures	-1.17	-1.19	-2.32	-8.52	-4.99
Sale of Property, Plant & Equipment	0.02	0.03	0.4	0.66	-
Cash Acquisitions	-	-	-	5.46	-
Divestitures	-	-	-	-0.57	-
Sale (Purchase) of Intangibles	-1.04	-0.73	-0.81	-0.07	-0.01
Investment in Securities	5.1	1.42	-17.16	-16.74	-8.82
Investing Cash Flow	2.91	-0.47	-19.88	-19.76	-13.81

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Issuance of Common Stock	0.59	25.87	2.64	-	-
Other Financing Activities	2.21	-1.49	-0.54	-	-
Financing Cash Flow	2.8	24.38	2.1	2.5	-

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Foreign Exchange Rate Adjustments	1.26	0.34	-0.27	-0.3	-1.89
Net Cash Flow	2.04	25.26	-21.7	8.33	-5.03

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Free Cash Flow	-6.11	-0.18	-5.96	17.38	5.69
Free Cash Flow Growth	-	-	-	205.25%	-
Free Cash Flow Margin	-5.56%	-0.15%	-5.63%	15.32%	5.56%
Free Cash Flow Per Share	-0.07	-0.00	-0.06	0.26	0.07
Levered Free Cash Flow	1.88	1.95	-6	20.67	-
Unlevered Free Cash Flow	1.88	1.95	-6	20.67	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash Income Tax Paid	5.62	5.62	8.52	6.35	6.31
Change in Working Capital	9.96	-18.26	-22.86	16.72	-7.8

SEC Filings: 10-K · 10-Q